Nutrition therapy cost analysis in the US

Robin Turpin (), Todd Canada, Frank Liu, Catherine Mercaldi, Alessandro Pontes-Arruda and Paul Wischmeyer

Applied Health Economics and Health Policy, 2011, vol. 9, issue 5, 292 pages

Abstract: In this analysis of real-world PN use, MCB PN is associated with lower costs than compounded PN with regards to both PN acquisition and potential avoidance of BSI. Our base case indicates that $US1545 per PN patient may be saved; even if as few as 50% of PN patients are candidates for standardized pre-mix formulations, a potential savings of $US773 per patient may be realized. Copyright Adis Data Information BV 2011

Date: 2011
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://hdl.handle.net/10.2165/11594980-000000000-00000 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:9:y:2011:i:5:p:281-292

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.2165/11594980-000000000-00000

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().